TEST:

Bloodhound™ MPN panel

The MPN panel provides comprehensive results in a simple workflow with 0.5% limit of detection for JAK2 V617F mutations and 2% limit of detection for other JAK2, MPL and CALR targets. At Precipio’s clinical lab, our Bloodhound Quantitative MPN panel is used to detect somatic mutations associated with various myeloproliferative neoplasms including Myelofibrosis, Polycythemia Vera (PV) and Essential Thrombocythemia (ET). The molecular panel quantifies allele frequencies of targeted mutations in JAK2 V617F, JAK2 Exon 12, JAK2 Exon 13, MPL, CALR type 1 and CALR type 2.